Globus Medical, Inc. (NYSE:GMED) Receives $106.36 Consensus Price Target from Analysts

Globus Medical, Inc. (NYSE:GMED) has been given an average recommendation of “Moderate Buy” by the fifteen brokerages that are currently covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $106.3636.

A number of equities research analysts have recently weighed in on GMED shares. Truist Financial set a $115.00 price target on Globus Medical in a research note on Wednesday, February 25th. Royal Bank Of Canada boosted their price target on Globus Medical from $115.00 to $120.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Wall Street Zen lowered Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Barclays boosted their price target on Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th.

Institutional Investors Weigh In On Globus Medical

A number of large investors have recently bought and sold shares of the company. Glenmede Trust Co. NA boosted its position in Globus Medical by 22.8% in the first quarter. Glenmede Trust Co. NA now owns 225,446 shares of the medical device company’s stock valued at $19,424,000 after buying an additional 41,801 shares during the last quarter. Summitry LLC boosted its position in Globus Medical by 2.6% in the first quarter. Summitry LLC now owns 8,205 shares of the medical device company’s stock valued at $707,000 after buying an additional 211 shares during the last quarter. Edgestream Partners L.P. purchased a new stake in Globus Medical in the first quarter valued at approximately $1,895,000. Janus Henderson Group PLC boosted its position in Globus Medical by 4.5% in the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock valued at $656,831,000 after buying an additional 328,217 shares during the last quarter. Finally, Arkadios Wealth Advisors boosted its position in Globus Medical by 10.6% in the first quarter. Arkadios Wealth Advisors now owns 3,255 shares of the medical device company’s stock valued at $280,000 after buying an additional 312 shares during the last quarter. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Price Performance

GMED opened at $82.00 on Wednesday. The business’s 50-day moving average is $87.01 and its two-hundred day moving average is $88.43. Globus Medical has a 1 year low of $51.79 and a 1 year high of $101.40. The firm has a market capitalization of $11.13 billion, a PE ratio of 19.07, a price-to-earnings-growth ratio of 1.69 and a beta of 0.95.

Globus Medical (NYSE:GMED) last posted its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The company had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. During the same quarter in the previous year, the firm earned $0.68 earnings per share. The firm’s quarterly revenue was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, sell-side analysts expect that Globus Medical will post 4.74 EPS for the current year.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.